<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cipla FY25 Q2 Result Update Report</title>
    <link rel="stylesheet" href="../style.css" />
</head>
<body>

    <h1>Cipla FY25 Q2 Result Update Report</h1>

    <h2>1. About</h2>
    <p>Cipla Limited is a leading Indian multinational pharmaceutical company focused on delivering high-quality, affordable medicines across over 80 markets. Cipla specializes in therapeutic areas such as respiratory, HIV/AIDS, cardiovascular, and urology, with a strong presence in both branded and generic pharmaceuticals.</p>

    <h2>2. Business</h2>
    <ul>
        <li><strong>Generics:</strong> Cipla is a major player in the global generics market with a strong pipeline of complex generics.</li>
        <li><strong>API Manufacturing:</strong> Cipla manufactures over 200 active pharmaceutical ingredients (APIs).</li>
        <li><strong>Respiratory Medicines:</strong> Cipla is a leader in respiratory treatments, especially in emerging markets.</li>
        <li><strong>Global Footprint:</strong> Cipla operates across India, North America, South Africa, and emerging markets.</li>
        <li><strong>Consumer Health:</strong> Expanding presence in the consumer health segment through recent acquisitions.</li>
    </ul>

    <h2>3. Why We Like the Company</h2>
    <ul>
        <li><strong>Strong R&D Capabilities:</strong> Significant investments in biosimilars, complex generics, and innovative treatments.</li>
        <li><strong>Resilient Growth:</strong> Consistent revenue growth driven by strong domestic and international performance.</li>
        <li><strong>Leadership in Respiratory Segment:</strong> Cipla's strong position in the respiratory drug market gives it a competitive edge.</li>
        <li><strong>Focus on Accessibility:</strong> Commitment to affordable healthcare across both developed and emerging markets.</li>
    </ul>

    <h2>4. Recent Updates</h2>
    <ul>
        <li><strong>Regulatory Developments:</strong> FDA inspections at Patalganga and Kurkumbh facilities requiring corrective actions.</li>
        <li><strong>Product Launch:</strong> Cipla launched a generic version of Lanreotide Injection in North America.</li>
        <li><strong>Strategic Acquisitions:</strong> Acquisitions of Ivia Beaute and additional shares in Achira Labs to strengthen consumer health and innovation capabilities.</li>
        <li><strong>Revenue Growth:</strong> Cipla posted 5% quarter-on-quarter revenue growth, driven by strong performance in India and North America.</li>
    </ul>

    <h2>5. Financial Projections (FY25-FY27)</h2>
    <table border="1">
        <tr>
            <th>Metric</th>
            <th>FY25</th>
            <th>FY26</th>
            <th>FY27</th>
        </tr>
        <tr>
            <td>Revenue (INR Cr)</td>
            <td>29,800</td>
            <td>31,500</td>
            <td>34,200</td>
        </tr>
        <tr>
            <td>EBITDA (INR Cr)</td>
            <td>7,400</td>
            <td>7,900</td>
            <td>8,600</td>
        </tr>
        <tr>
            <td>OPM (%)</td>
            <td>24.8%</td>
            <td>25.1%</td>
            <td>25.2%</td>
        </tr>
        <tr>
            <td>PAT (INR Cr)</td>
            <td>4,900</td>
            <td>5,200</td>
            <td>5,600</td>
        </tr>
        <tr>
            <td>EPS (INR)</td>
            <td>60.7</td>
            <td>64.4</td>
            <td>69.3</td>
        </tr>
        <tr>
            <td>P/E</td>
            <td>27x</td>
            <td>26x</td>
            <td>24x</td>
        </tr>
        <tr>
            <td>RoCE (%)</td>
            <td>17.5%</td>
            <td>18.0%</td>
            <td>18.5%</td>
        </tr>
        <tr>
            <td>ROE (%)</td>
            <td>15.4%</td>
            <td>16.1%</td>
            <td>16.8%</td>
        </tr>
    </table>

</body>
</html>
